In addition, we also identified the activity of ‘MAPK inactivation of SMRT corepressor pathway’ as a good predictive biomarker for the sensitivity of EGFR-activated NSCLC cell lines to EGFR inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.